ArticleLeukemia2020
Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Complexities of Measurable Residual Disease Assays in Acute Lymphoblastic Leukemia: A Guide for the Practicing Clinician.Acta haematologica · 2026Review
- Article
- Measurable residual disease in hematologic malignancies: a biomarker in search of a standard.EClinicalMedicine · 2025Review
- [Current situation and prospect of minimal residual disease in pediatric T cell acute lymphoblastic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia.British journal of haematology · 2025Article
- How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings.Cancers · 2023Review
- Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications.Frontiers in immunology · 2023Article
- MRD in ALL: Optimization and Innovations.Current hematologic malignancy reports · 2022Review
- MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?Hematology. American Society of Hematology. Education Program · 2021Article
- Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.Blood advances · 2021Observational
- Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.Current oncology (Toronto, Ont.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31641191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.